Findings

What do systematic reviews say?

5 questions · 5 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 60%Low 0 · 0%Moderate 2 · 40%High 0 · 0%

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

It is very uncertain whether two weeks of AmBd + 5FC + FLU changes mortality: 10 weeks compared with two weeks of AmBd + FLU (very low certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.43 [0.13, 1.37]
1 study · 32 participants
Very low

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

It is very uncertain whether two weeks of AmBd + 5FC + FLU changes mortality: 10 weeks compared with two weeks of AmBd + 5FC (very low certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 2.81 [0.33, 24.16]
1 study · 31 participants
Very low

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

It is very uncertain whether two weeks of AmBd + 5FC + FLU changes mortality: 10 weeks compared with two weeks of AmBd (very low certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 1 [0.24, 4.23]
1 study · 32 participants
Very low

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

Two weeks of 5FC + FLU showed no clear difference in mortality: 10 weeks compared with two weeks of AmBd + FLU (moderate certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.85 [0.64, 1.13]
1 study · 339 participants
Moderate

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

Two weeks of 5FC + FLU showed no clear difference in mortality: 10 weeks compared with two weeks of AmBd + 5FC (moderate certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.92 [0.69, 1.23]
1 study · 340 participants
Moderate